President Donald Trump in a press conference on Thursday said the Food and Drug Administration is fast-tracking efforts to approve an antiviral therapy, best known for treating malaria, for use in coronavirus cases. 

The drug, hydroxychloroquine, was developed more than a half-century ago and is approved for treating malaria, arthritis, and other ailments. Reports out of China and Italy suggest the drug may help, but there is no hard data yet.

"We're going to be able to make that drug available almost immediately," Trump said. 

The FDA is working to conduct a "large, pragmatic clinical trial" quickly to confirm the drug's benefit to coronavirus patients, said Commissioner Dr. Stephen Hahn.

He also tempered the president's optimism about the still-untested solution. 

"What's also important is not to provide false hope," he said. "We may have the right drug, but it might not be in the appropriate dosage form right now, and it might do more harm than good."

New antiviral therapies face a shorter and less arduous approval process than vaccines, several of which are under development with 12 to 18-month timelines.  

"The therapies are something we could move on much faster potentially," Trump said. 

He claimed the administration "slashed red tape" to develop new vaccines and therapies.

The president also held out on confirming whether he would invoke the Defense Production Act, which he signed on Wednesday, to mandate the production of needed medical supplies such as N95 respirators and surgical masks

"If we find that we need something, then we will do that," he said.  

Trump repeated that he was open to the federal government buying equity stakes in the airline, cruise, hospitality, and other industries hurt by the outbreak. 

The press conference opened with more controversial language placing the blame squarely on China for the outbreak, despite concerns voiced about potentially exacerbating a backlash against Asian Americans.

"We continue our relentless effort to defeat the Chinese virus," Trump said.

Share:
More In Politics
Keep an Eye on These Politicians in 2022
As the 2022 midterm elections fast approach, here are some politicians Americans should be on the lookout for. Democratic Massachusetts state senator Sonia Chang-Diaz, who was the first Latina and Asian American woman to be elected to the state's senate, now has her eye on the governorship with Republican Charlie Baker leaving. New Jersey GOP candidate for Congress, Billy Prempeh also bears watching, and while Boston's newest mayor, Democrat Michelle Wu, was already sworn in last month, all eyes will be on Beantown as the first woman and first person of color to hold the office tries to usher in a new era for the city.
Why Democrats Losing Hispanic Voters
Chuck Rocha, host of 'Nuestro' podcast and opinion contributor at The New York Times, joins Cheddar News to discuss why Democrats are losing Hispanic voters.
Return-to-Office Mandates Might Be Hurting the Middle Class
More businesses are requiring workers to return to the office, but there is concern that many employees in the middle class, especially women and people of color, need remote work options for reasons including childcare and financial security. Joan Williams, director of the Center for WorkLife Law at the University of California, joined Cheddar to discuss why office mandates could be detrimental to the middle class. She noted that while companies claim a return to offices would help foster more collaboration and efficiency, reports show that they are successfully able to do their jobs from home.
California Governor Explores Texas-Like Law to Ban Assault Weapons
The U.S. Supreme Court ruled to allow the controversial Texas abortion law to remain in effect, banning abortion at six weeks and allowing any private citizen to sue a person or doctor aiding or abetting someone seeking an abortion. Outraged at this decision, California Governor Gavin Newsom is working to draft a proposal in line with the law as it relates to guns. Shawn Hubler, California correspondent at the New York Times, joins Cheddar News to discuss.
Load More